Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2020

Open Access 01-12-2020 | Carbapenem Antibiotic | Research

Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia

Authors: Fang-Yu Kang, Chorng-Kuang How, Yung-Chih Wang, Aristine Cheng, Ya-Sung Yang, Shu-Chen Kuo, Chang-Pan Liu, Yuag-Meng Liu, Te-Li Chen, Yi-Tzu Lee

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2020

Login to get access

Abstract

Background

The impact of appropriate antimicrobial therapy for A. baumannii bacteremic pneumonia has not been well established due to the inclusion of the three phenotypically indistinguishable Acinetobacter species and confounding factors including underlying diseases and severity of infection. This retrospective study aimed to evaluate the impact of appropriate antimicrobial therapy on 14-day mortality in A. baumannii bacteremic pneumonia patients after adjusting for risk factors.

Methods

This study was conducted at five medical centers in Taiwan between July 2012 and June 2016. A. baumannii species identification was performed using reference molecular methods. Risk factors for 14-day mortality were analyzed via logistic regression. The interaction between the Acute Physiology and Chronic Health Evaluation (APACHE) II score and appropriate antimicrobial therapy was assessed using the logistic model.

Results

A total of 336 patients with monomicrobial A. baumannii bacteremic pneumonia were included in this study. The overall 14-day mortality rate was 47.3%. The crude mortality of appropriate antimicrobial therapy was 35.9% (57 of 151 patients). Appropriate antimicrobial therapy was associated with a lower mortality after multivariate adjustment (odds ratio [OR], 0.57; 95% confidence interval [CI], 0.34–0.97; p = 0.04), and the effect was influenced by APACHE II score (OR for interaction term, 0.0098; 95% CI, 0.0005–0.1885; p = 0.002). Further analysis demonstrated that appropriate antimicrobial therapy significantly reduced 14-day mortality among the patients with an APACHE II score > 35 (OR 0.0098; 95% CI 0.0005–0.1885).

Conclusion

Appropriate antimicrobial therapy decreases 14-day mortality of the most severely ill patients with A. baumannii bacteremic pneumonia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alp E, Güven M, Yildiz O, Aygen B, Voss A, Doganay M. Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study. Ann Clin Microbiol Antimicrob. 2004;3:17.PubMedPubMedCentralCrossRef Alp E, Güven M, Yildiz O, Aygen B, Voss A, Doganay M. Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study. Ann Clin Microbiol Antimicrob. 2004;3:17.PubMedPubMedCentralCrossRef
2.
go back to reference Leu HSKD, Mori M, Woolson RF, Wenzel RP. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol. 1989;129(6):1258–67.PubMedCrossRef Leu HSKD, Mori M, Woolson RF, Wenzel RP. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol. 1989;129(6):1258–67.PubMedCrossRef
3.
go back to reference Chang HC, Chen YC, Lin MC, Liu SF, Chung YH, Su MC, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. J Formos Med Assoc. 2011;110(9):564–71.PubMedCrossRef Chang HC, Chen YC, Lin MC, Liu SF, Chung YH, Su MC, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. J Formos Med Assoc. 2011;110(9):564–71.PubMedCrossRef
4.
go back to reference Cisneros-Herreros JM, Garnacho-Montero J, Pachon-Ibanez ME. Nosocomial pneumonia due to Acinetobacter baumannii. Enferm Infecc Microbiol Clin. 2005;23(Suppl 3):46–51.PubMedCrossRef Cisneros-Herreros JM, Garnacho-Montero J, Pachon-Ibanez ME. Nosocomial pneumonia due to Acinetobacter baumannii. Enferm Infecc Microbiol Clin. 2005;23(Suppl 3):46–51.PubMedCrossRef
5.
go back to reference Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993;94(3):281–8.PubMedCrossRef Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993;94(3):281–8.PubMedCrossRef
6.
go back to reference Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacaro JA, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31(5):649–55.PubMedCrossRef Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacaro JA, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31(5):649–55.PubMedCrossRef
7.
go back to reference Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36(11):1999–2006.PubMedCrossRef Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36(11):1999–2006.PubMedCrossRef
8.
go back to reference Brotfain E, Borer A, Koyfman L, Saidel-Odes L, Frenkel A, Gruenbaum SE, et al. Multidrug resistance Acinetobacter bacteremia secondary to ventilator-associated pneumonia: risk factors and outcome. J Intensive Care Med. 2017;32(9):528–34.PubMedCrossRef Brotfain E, Borer A, Koyfman L, Saidel-Odes L, Frenkel A, Gruenbaum SE, et al. Multidrug resistance Acinetobacter bacteremia secondary to ventilator-associated pneumonia: risk factors and outcome. J Intensive Care Med. 2017;32(9):528–34.PubMedCrossRef
9.
go back to reference Ellis D, Cohen B, Liu J, Larson E. Risk factors for hospital-acquired antimicrobial-resistant infection caused by Acinetobacter baumannii. Antimicrob Resist Infect Control. 2015;4:40.PubMedPubMedCentralCrossRef Ellis D, Cohen B, Liu J, Larson E. Risk factors for hospital-acquired antimicrobial-resistant infection caused by Acinetobacter baumannii. Antimicrob Resist Infect Control. 2015;4:40.PubMedPubMedCentralCrossRef
10.
go back to reference Kanafani ZA, Zahreddine N, Tayyar R, Sfeir J, Araj GF, Matar GM, et al. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resist Infect Control. 2018;7:9.PubMedPubMedCentralCrossRef Kanafani ZA, Zahreddine N, Tayyar R, Sfeir J, Araj GF, Matar GM, et al. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resist Infect Control. 2018;7:9.PubMedPubMedCentralCrossRef
11.
go back to reference Čiginskienė A, Dambrauskienė A, Rello J, Adukauskienė D. Ventilator-associated pneumonia due to drug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles, and independent predictors of in-hospital mortality. Medicina (Kaunas). 2019;55(2):49. Čiginskienė A, Dambrauskienė A, Rello J, Adukauskienė D. Ventilator-associated pneumonia due to drug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles, and independent predictors of in-hospital mortality. Medicina (Kaunas). 2019;55(2):49.
12.
go back to reference Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13(1):97–103.PubMedPubMedCentralCrossRef Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13(1):97–103.PubMedPubMedCentralCrossRef
13.
go back to reference Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Inf Secur. 2010;61(3):212–8. Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Inf Secur. 2010;61(3):212–8.
14.
go back to reference Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am J Infect Control. 2013;41(7):e59–63.PubMedCrossRef Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am J Infect Control. 2013;41(7):e59–63.PubMedCrossRef
15.
go back to reference Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2005;38(2):127–36.PubMed Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2005;38(2):127–36.PubMed
16.
go back to reference Chusri S, Chongsuvivatwong V, Silpapojakul K, Singkhamanan K, Hortiwakul T, Charernmak B, Doi Y. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2019;52(5):796-806. Chusri S, Chongsuvivatwong V, Silpapojakul K, Singkhamanan K, Hortiwakul T, Charernmak B, Doi Y. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2019;52(5):796-806.
17.
go back to reference Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34(6):575–9.PubMedCrossRef Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34(6):575–9.PubMedCrossRef
18.
go back to reference Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis. 2012;55(2):209–15.PubMedCrossRef Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis. 2012;55(2):209–15.PubMedCrossRef
19.
go back to reference Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.PubMedPubMedCentralCrossRef Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.PubMedPubMedCentralCrossRef
20.
go back to reference Pogue JM, Ortwine JK, Kaye KS. Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing. Clin Microbiol Infect. 2017;23(4):229–33.PubMedCrossRef Pogue JM, Ortwine JK, Kaye KS. Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing. Clin Microbiol Infect. 2017;23(4):229–33.PubMedCrossRef
21.
go back to reference Chen TL, Siu LK, Wu RC, Shaio MF, Huang LY, Fung CP, et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect. 2007;13(8):801–6.PubMedCrossRef Chen TL, Siu LK, Wu RC, Shaio MF, Huang LY, Fung CP, et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect. 2007;13(8):801–6.PubMedCrossRef
22.
go back to reference Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30(2):557–96.PubMedPubMedCentralCrossRef Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30(2):557–96.PubMedPubMedCentralCrossRef
23.
go back to reference Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant gram-negative bacilli. J Clin Microbiol. 2013;51(6):1678–84.PubMedPubMedCentralCrossRef Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant gram-negative bacilli. J Clin Microbiol. 2013;51(6):1678–84.PubMedPubMedCentralCrossRef
24.
go back to reference Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother. 2005;49(9):3903–9.PubMedPubMedCentralCrossRef Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother. 2005;49(9):3903–9.PubMedPubMedCentralCrossRef
25.
go back to reference Hosseini M, Ramazani J. Evaluation of acute physiology and chronic health evaluation II and sequential organ failure assessment scoring systems for prognostication of outcomes among intensive care Unit's patients. Saudi J Anaesth. 2016;10(2):168–73.PubMedPubMedCentralCrossRef Hosseini M, Ramazani J. Evaluation of acute physiology and chronic health evaluation II and sequential organ failure assessment scoring systems for prognostication of outcomes among intensive care Unit's patients. Saudi J Anaesth. 2016;10(2):168–73.PubMedPubMedCentralCrossRef
26.
go back to reference Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis. 2007;44(1):87–93.PubMedCrossRef Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis. 2007;44(1):87–93.PubMedCrossRef
27.
go back to reference Lin YT, Chuang C, Su CF, Chan YJ, Wang LS, Huang CT, et al. Efficacy of appropriate antimicrobial therapy on the survival of patients with Carbapenem nonsusceptible Klebsiella Pneumoniae infection: a multicenter study in Taiwan. Medicine (Baltimore). 2015;94(33):e1405.PubMedCentralCrossRef Lin YT, Chuang C, Su CF, Chan YJ, Wang LS, Huang CT, et al. Efficacy of appropriate antimicrobial therapy on the survival of patients with Carbapenem nonsusceptible Klebsiella Pneumoniae infection: a multicenter study in Taiwan. Medicine (Baltimore). 2015;94(33):e1405.PubMedCentralCrossRef
28.
go back to reference Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med. 2003;31(10):2478–82.PubMedCrossRef Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med. 2003;31(10):2478–82.PubMedCrossRef
29.
go back to reference Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis. 2011;52(3):352–60.PubMedCrossRef Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis. 2011;52(3):352–60.PubMedCrossRef
30.
go back to reference Lee NY, Chang TC, Wu CJ, Chang CM, Lee HC, Chen PL, et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Inf Secur. 2010;61(3):219–27. Lee NY, Chang TC, Wu CJ, Chang CM, Lee HC, Chen PL, et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Inf Secur. 2010;61(3):219–27.
31.
go back to reference Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2012;64(3):282–90.PubMedCrossRef Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2012;64(3):282–90.PubMedCrossRef
32.
go back to reference Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592–7.PubMedPubMedCentralCrossRef Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592–7.PubMedPubMedCentralCrossRef
33.
go back to reference Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess mortality associated with Colistin-Tigecycline compared with Colistin-Carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015;43(6):1194–204.PubMedCrossRef Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess mortality associated with Colistin-Tigecycline compared with Colistin-Carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015;43(6):1194–204.PubMedCrossRef
34.
go back to reference Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065–72.PubMedPubMedCentralCrossRef Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065–72.PubMedPubMedCentralCrossRef
35.
go back to reference Ambrose PG, Hammel JP, Bhavnani SM, Rubino CM, Ellis-Grosse EJ, Drusano GL. Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics. Antimicrob Agents Chemother. 2012;56(3):1466–70.PubMedPubMedCentralCrossRef Ambrose PG, Hammel JP, Bhavnani SM, Rubino CM, Ellis-Grosse EJ, Drusano GL. Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics. Antimicrob Agents Chemother. 2012;56(3):1466–70.PubMedPubMedCentralCrossRef
36.
go back to reference Liou BH, Lee YT, Kuo SC, Liu PY, Fung CP. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure. Antimicrob Agents Chemother. 2015;59(6):3637–40.PubMedPubMedCentralCrossRef Liou BH, Lee YT, Kuo SC, Liu PY, Fung CP. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure. Antimicrob Agents Chemother. 2015;59(6):3637–40.PubMedPubMedCentralCrossRef
37.
38.
go back to reference Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102.PubMedPubMedCentralCrossRef Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102.PubMedPubMedCentralCrossRef
Metadata
Title
Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia
Authors
Fang-Yu Kang
Chorng-Kuang How
Yung-Chih Wang
Aristine Cheng
Ya-Sung Yang
Shu-Chen Kuo
Chang-Pan Liu
Yuag-Meng Liu
Te-Li Chen
Yi-Tzu Lee
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2020
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-020-00824-4

Other articles of this Issue 1/2020

Antimicrobial Resistance & Infection Control 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.